Sirnaomics Ltd. (2257) AI Stock Analysis

• Market Cap: HK$1.09B
• Dividend Yield: N/A
• Average Volume (3M): 442.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: N/A
• EPS Growth: 83.89%
• Country: HK
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 107,221,535
• 10 Day Avg. Volume: 408,789
• 30 Day Avg. Volume: 442,620
• PEG Ratio: 0.02
• Price to Book (P/B): -20.53
• Price to Sales (P/S): 19.40
• P/FCF Ratio: -1.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: HK$8.50 ▲(6.25% Upside)

The score is primarily weighed down by weak financial performance (ongoing losses, negative equity, and negative free cash flow). Technical indicators are mixed and provide only modest support, while valuation is constrained by a loss-making profile and no dividend yield data.

Positive Factors

Proprietary RNAi platform

A proprietary siRNA design and optimization platform is a durable competitive asset in RNAi therapeutics. It supports differentiated drug candidates, faster iterative R&D, and stronger licensing or partnership leverage, enabling sustainable pipeline growth and long-term value creation.

High gross margin on core activity

A 67.4% gross margin indicates favorable underlying economics for the company’s therapeutic manufacturing or licensing revenue. If operating expenses are managed or shifted via partnerships, this margin provides a structural path toward profitability and scalable unit economics over the medium term.

Diversified funding and partnerships

Multiple funding sources—product sales, grants, and collaborations—reduce reliance on a single revenue stream. Grants and milestone-based partnership payments can be durable non-dilutive or staged funding, supporting ongoing R&D and clinical programs over the next several months.

Negative Factors

Deep operating losses

A net margin of -289% signals severe operating losses that erode capital and impair reinvestment capacity. Sustained large losses force reliance on external financing or major restructuring, constraining strategic options and increasing dilution or program cuts over a 2–6 month horizon.

Negative stockholders' equity

Negative shareholders' equity reflects accumulated deficits and raises insolvency concerns. It limits access to debt markets, can breach covenants, and reduces financial flexibility. Management must secure financing or partnerships, increasing strategic pressure and dilution risk in the medium term.

Material negative free cash flow

Persistently negative free cash flow, despite recent improvement, indicates ongoing cash burn that threatens runway. Unless cash generation turns positive or material external funding is secured, the company may need dilutive equity raises or asset monetization, affecting long-term program continuity.

Sirnaomics Ltd. Business Overview & Revenue Model

Company Description

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Sirnaomics generates revenue primarily through a combination of product sales, research grants, and collaborations with other pharmaceutical companies. The company's revenue model is driven by the successful development and commercialization of its RNAi therapeutics, which may include upfront payments, milestone payments, and royalties from licensing agreements. Additionally, Sirnaomics may receive funding from government and private research grants that support its innovative research initiatives. Strategic partnerships with larger pharmaceutical firms can also provide significant financial backing and resources, enabling Sirnaomics to accelerate its drug development processes and expand its market presence.

Sirnaomics Ltd. Financial Statement Overview

Summary

Sirnaomics Ltd. faces significant financial challenges with persistent operating losses and a weak balance sheet characterized by negative equity. Despite some revenue growth and improvements in free cash flow, the company remains unprofitable with high cash burn, raising concerns about its ability to sustain operations without further financing.

Income Statement

The company's income statement reveals ongoing challenges in profitability and revenue growth. Despite an increase in revenue from the previous year, the net profit margin remains deeply negative at -289.0% for 2024, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Although the gross profit margin is positive at 67.4%, it is insufficient to offset the high operating expenses.

Balance Sheet

The balance sheet indicates a precarious financial position with negative stockholders' equity, signaling insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, but the company has managed to maintain a relatively low total debt level. The equity ratio is negative, reflecting a higher liability level than assets, which poses a financial stability risk.

Cash Flow

The cash flow statement shows a significant negative free cash flow, indicating cash burn exceeding income. The operating cash flow to net income ratio is negative, highlighting cash outflows in operations. However, there is a noticeable improvement in free cash flow, which grew positively from 2023 to 2024, suggesting some progress towards better cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	949.00K	1.78M	397.00K	705.00K	0.00	0.00
Gross Profit	370.00K	1.20M	397.00K	705.00K	-12.67M	0.00
EBITDA	-15.48M	-31.12M	-72.36M	-89.02M	-1.66B	-19.27M
Net Income	-14.02M	-51.38M	-78.69M	-88.30M	-1.66B	-43.77M
Balance Sheet
Total Assets	21.30M	28.33M	75.79M	163.93M	240.65M	110.18M
Cash, Cash Equivalents and Short-Term Investments	6.87M	11.77M	43.93M	105.23M	211.99M	103.12M
Total Debt	7.21M	8.06M	8.85M	10.76M	7.04M	91.87M
Total Liabilities	40.40M	44.33M	51.33M	52.37M	30.36M	204.36M
Stockholders Equity	-5.12M	-1.68M	40.20M	122.01M	211.62M	-94.43M
Cash Flow
Free Cash Flow	-9.26M	-19.84M	-72.03M	-107.54M	-62.85M	-21.15M
Operating Cash Flow	-9.26M	-19.73M	-70.29M	-88.71M	-56.97M	-19.00M
Investing Cash Flow	1.94M	2.14M	-5.35M	-32.61M	-6.04M	8.39M
Financing Cash Flow	6.53M	5.82M	-5.61M	15.89M	170.96M	100.37M

Sirnaomics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Positive. The current price of 8 is below the 20-day moving average (MA) of 8.42, below the 50-day MA of 8.31, and above the 200-day MA of 7.82, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 70.18 is Negative, neither overbought nor oversold. The STOCH value of 95.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2257.

Sirnaomics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	61 Neutral	HK$1.93B	238.10	0.99%	―	9.41%	-32.69%
2197	52 Neutral	HK$3.76B	-3.61	―	―	79.98%	-3.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3681	45 Neutral	HK$2.35B	-11.90	-55.33%	―	-100.00%	30.68%
2257	44 Neutral	HK$1.09B	-8.04	―	―	―	83.89%
2616	42 Neutral	HK$8.41B	-18.58	-95.84%	―	-55.64%	-158.67%
6628	41 Neutral	HK$1.07B	-3.43	-34.18%	―	-57.84%	24.58%

Sirnaomics Ltd. Corporate Events

Sirnaomics Completes Phase I Trial of Cancer Drug STP707 and Files Clinical Report with FDA

Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a Phase I clinical trial of its investigational cancer drug STP707 in adults with advanced, metastatic or inoperable solid tumors that were no longer responding to standard treatments. The study showed that STP707, administered intravenously at various dose levels, demonstrated meaningful clinical activity with some patients achieving stable disease and a slowing of tumor progression, while side effects remained mostly manageable. The company has formally submitted the Clinical Study Report to the U.S. Food and Drug Administration, a milestone that positions it to begin discussions on the design and strategy for a Phase II development program, although it cautions there is no guarantee the candidate will ultimately be successfully developed or commercialized.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Chairman Increases Stake, Signaling Confidence in Growth

Sirnaomics Ltd. announced that Dr. Poon Hung Fai, the company’s chairman and executive director, has increased his shareholding by purchasing 100,000 ordinary shares at an average price of HK$6.83 per share. This move reflects Dr. Poon’s confidence in the company’s growth prospects and potential development. The acquisition raises his total shareholding to 16.44% of the company’s issued share capital, signaling strong insider confidence, which may positively influence investor sentiment.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Completes Partial Share Subscription to Boost Drug Development

Sirnaomics Ltd. announced the partial completion of a subscription agreement, resulting in the issuance of 1,003,700 new shares to Subscriber B at HK$12.00 per share. The termination of the remaining shares in the agreement was mutually agreed upon, with no adverse impact on the company’s operations or financial conditions. The net proceeds of approximately HK$12.0 million will be used for the development and commercialization of their drug candidates, enhancing the company’s strategic focus on advancing its RNAi therapeutics portfolio.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Announces Board of Directors and Committee Roles

Sirnaomics Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to the audit, nomination, and remuneration committees. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders and investors to understand the leadership dynamics and decision-making processes within the organization.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Successfully Implements Remedial Actions for Internal Control

Sirnaomics Ltd. has announced the completion of its remedial actions to address internal control weaknesses and deficiencies, as identified in a recent internal control review. The company engaged PAL Advisory Limited to assess the effectiveness of these actions, particularly focusing on business communication standards. The review confirmed that the company’s measures, including mandatory training and policy updates, have adequately addressed the issues, thereby enhancing data security and compliance within the organization.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.